



"Based on the promising information from research to date, I am confident that by participating in this trial, the best possible outcomes will be achieved for me. In the process, I am pleased to do my bit to help advance science and accelerate the availability of a novel drug that will save future patients' lives."

Pieter Jagtenberg, Patient

Pieter Jagtenberg

Meet Pieter; he is one of the 4,500+ people diagnosed with pancreatic cancer in Australia each year. For people like Pieter and his family, research and clinical trials provide hope at a time when hope can be in short supply.

In early 2005 Pieter Jagtenberg immigrated to Australia to progress his career in engineering. Accompanied by his wife, Tina, and three young children, they settled in Perth and were welcomed into the local community.

By early 2020, Pieter and Tina were empty nesters, leaving them to experience the romance of the open road on various adventures across Western Australia's captivating landscapes and rediscover their backyard. Apart from some niggling 'gas' pain that Pieter self-diagnosed as an emerging lactose intolerance, he felt fit and healthy. Life was good.

After removing dairy from his diet, the familiar travelling pain he had become accustomed to stopped, which unmasked a consistent, focused pain in his upper abdomen. Usually not a fan of GP visits, the signs worried Pieter enough to make an appointment in February 2023. By early March, the results of the initial CT scan revealed abnormalities consistent with pancreatic cancer.

Thanks to his proactive GP, Pieter was immediately referred to a specialist team of surgeons, gastroenterologists and endoscopists. The initial diagnosis and time spent waiting on additional scans and test results took a mental toll on the outcomes-focused and action-driven Pieter. Knowing the importance of time, particularly when dealing with a diagnosis of an aggressive cancer type, Pieter was keen to have a clear treatment and battle plan. As 'fortune' would have it, Pieter's diagnosis coincided with the start of recruitment for the i-LSTA trial, and he eagerly agreed to be the first patient to participate.

"The iLSTA Trial is potentially the first major opportunity we have to enable immunotherapy to fully engage against pancreatic cancer. It is an important step in our mission to create new hope for patients by providing meaningful treatment options."

**Meg Croucher,
WARPNINE CEO**

Clinical trials and research are essential to developing new treatments and fundamental to giving patients and their families hope and more time.

The extraordinary support of the WARPNINE community has enabled WARPNINE to sponsor this innovative and potentially game-changing trial and give families like Pieter's hope at a time when it can be in short supply.

The work we strive to support goes beyond laboratories and doctors' rooms. It touches the lives of people like Pieter. Your support of WARPNINE will help us support more patient-focused projects and trials so that more patients like Pieter can access the care and treatment options they need.

Please give as generously as you can this tax time so that we can continue to charge at warp speed to find the cancer treatments of the future.



Pieter at Nature's Window in Kalbarri